Summary of COVID-19 ropeginterferon alfa-2b studies

1. Liu et al., A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19

132 patient ropeginterferon alfa-2b early treatment RCT: 90% lower ventilation (p=0.04), 3% higher need for oxygen therapy (p=1), and 4% improved recovery (p=1).
RCT 132 hospitalized moderate COVID-19 patients in Taiwan showing higher rates of viral clearance or discharge by day 11 with ropeginterferon alfa-2b. The ropeginterferon alfa-2b group also showed higher rates of improvement in lung infiltration on day 5 and WHO clinical progression scores on day 8. There was no significant difference in mortality.
May 2024, Infectious Diseases and Therapy, https://link.springer.com/10.1007/s40121-024-00992-5, https://c19p.org/liu20